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Hisao Ogawa, MD, PHD,*kkk for the PRECISE–IVUS InvestigatorsABSTRACTBACKGROUND Despite standard statin therapy, amajority of patients retain a high “residual risk”of cardiovascular events.
OBJECTIVES The aim of this study was to evaluate the effects of ezetimibe plus atorvastatin versus atorvastatin
monotherapy on the lipid proﬁle and coronary atherosclerosis in Japanese patients who underwent percutaneous
coronary intervention (PCI).
METHODS This trial was a prospective, randomized, controlled, multicenter study. Eligible patients who underwent PCI
were randomly assigned to atorvastatin alone or atorvastatin plus ezetimibe (10mg) daily. Atorvastatin was uptitratedwith
a treatment goal of low-density lipoprotein cholesterol (LDL-C)<70mg/dl. Serial volumetric intravascular ultrasound was
performed at baseline and again at 9 to 12 months to quantify the coronary plaque response in 202 patients.
RESULTS The combination of atorvastatin/ezetimibe resulted in lower levels of LDL-C than atorvastatin monotherapy
(63.2  16.3 mg/dl vs. 73.3  20.3 mg/dl; p < 0.001). For the absolute change in percent atheroma volume (PAV),
the mean difference between the 2 groups (–1.538%; 95% conﬁdence interval [CI]: –3.079% to 0.003%) did not
exceed the pre-deﬁned noninferiority margin of 3%, but the absolute change in PAV did show superiority for the dual
lipid-lowering strategy (–1.4%; 95% CI: –3.4% to –0.1% vs. –0.3%; 95% CI: –1.9% to 0.9% with atorvastatin alone;
p ¼ 0.001). For PAV, a signiﬁcantly greater percentage of patients who received atorvastatin/ezetimibe showed coronary
plaque regression (78% vs. 58%; p ¼ 0.004). Both strategies had acceptable side effect proﬁles, with a low incidence
of laboratory abnormalities and cardiovascular events.
CONCLUSIONS Compared with standard statin monotherapy, the combination of statin plus ezetimibe showed greater
coronary plaque regression, which might be attributed to cholesterol absorption inhibition–induced aggressive lipid
lowering. (Plaque Regression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by Intravascular
Ultrasound [PRECISE-IVUS]; NCT01043380) (J Am Coll Cardiol 2015;66:495–507) © 2015 by the American College of
Cardiology Foundation.
ABBR EV I A T I ON S
AND ACRONYMS
ACC = American College of
Cardiology
ACS = acute coronary
syndrome(s)
AHA = American Heart
Association
CAD = coronary artery disease
CSA = cross-sectional area
CV = cardiovascular
EEM = external elastic
membrane
HDL-C = high-density
lipoprotein cholesterol
IVUS = intravascular
ultrasound
L = atorvastatin alone group
LDL-C = low-density
lipoprotein cholesterol
LZ = atorvastatin plus
ezetimibe group
PAV = percent atheroma
volume
PCI = percutaneous coronary
intervention
SAP = stable angina pectoris
TAV = total atheroma volume
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496P ivotal large-scale clinical trials of sec-ondary preventive measures in pa-tients with coronary artery disease
(CAD) have shown that 3-hydroxy-3-methyl-
glutaryl coenzyme A reductase inhibitors
(statins) reduce cardiovascular (CV) events
and atherogenic lipoproteins (e.g., low-
density lipoprotein cholesterol [LDL-C])
(1–3). The latest American College of Cardiol-
ogy/American Heart Association (ACC/AHA)
guidelines focus on a healthy lifestyle
together with a higher dose of statins without
titration to a speciﬁc LDL-C target, which
eliminates the need for additional medica-
tions (4). However, despite the current trend
of aggressive lipid-lowering strategies, the
majority of patients continue to experience
CV events and remain exposed to high “resid-
ual risk” of future acute CV events. Therefore,
additional novel pharmacologic strategies for
the prevention of additional CV events risk
remain essential, particularly for high-risk
atherosclerotic CV disease patients (e.g., pa-
tients with diabetes, familial hypercholester-
olemia, or acute coronary syndrome [ACS]).SEE PAGE 508In IMPROVE–IT (Improved Reduction of Outcomes:
Vytorin Efﬁcacy International Trial) investigators
compared simvastatin with a placebo or simvastatin
with ezetimibe (5). Both drugs reduce LDL-C levels,
but in different ways: simvastatin blocks hepatic*Department of Cardiovascular Medicine, Graduate School of M
betes Care Center, Cardiovascular Division, Jinnouchi Hospital, Ku
spital, Kumamoto, Japan; xDepartment of Cardiovascular Medic
ision of Cardiology, Social Insurance Omuta Tenryo Hospital, Omu
General Hospital, Hitoyoshi, Japan; #Division of Cardiology, Sa
, Japan; **Interventional Cardiology Unit, New Tokyo Hospital, M
t of Internal Medicine, Hyogo College of Medicine, Nishinomi
University, Kumamoto, Japan; xxDivision of Cardiology, Amak
, Shin-Beppu Hospital, Beppu, Japan; {{Division of Cardiology
ivision of Cardiology, Health Insurance Kumamoto General Hos
or Health and Welfare Organization Kumamoto Rosai Hospital
ospital Organization Kumamoto Medical Center, Kumamoto, Ja
Hospital, Kumamoto, Japan; xxxDivision of Cardiology, Kum
ent of Cardiovascular Medicine, National Cerebral and Cardiovas
Grant-in-Aid for Young Scientists B (22790713, 24790769) and a G
ry of Education, Science, and Culture, Japan (to Dr. Tsujita). Dr.
hringer Ingelheim, Daiichi-Sankyo, MSD, Pﬁzer, and Takeda; ha
chi-Sankyo, and Novartis; and has received scholarship funds from
kyo, Dainippon Sumitomo Pharma, Kowa, MSD, Otsuka, Pﬁzer, Sa
ion for lectures from MSD. All other authors have reported that th
to disclose.
his manuscript’s audio summary by JACC Editor-in-Chief Dr. Vale
t received April 5, 2015; revised manuscript received May 8, 2015cholesterol synthesis, whereas ezetimibe reduces
cholesterol absorption through inhibition of
the Niemann-Pick C1-like1 protein. Compared with
simvastatin with a placebo, simvastatin plus 10 mg of
ezetimibe daily led to a signiﬁcantly lower incidence
of the primary combined CV endpoint (CV death,
myocardial infarction, rehospitalization for unstable
angina, coronary revascularization, or stroke; 34.7%
vs. 32.7%; p ¼ 0.016) (6). This was the ﬁrst trial to
demonstrate the incremental clinical beneﬁt of
adding a nonstatin agent to standard statin therapy.
However, whether the additional LDL-C lowering
achieved when adding ezetimibe to statin therapy
will lead to stronger coronary plaque regression is
currently unknown. Also, it is not well understood
whether using a dual lipid-lowering strategy (sole
inhibition of cholesterol synthesis vs. combined in-
hibition of synthesis and absorption) affects plaque
progression and/or regression. Thus, the PRECISE-
IVUS (Plaque Regression With Cholesterol Absorp-
tion Inhibitor or Synthesis Inhibitor Evaluated by
Intravascular Ultrasound) trial was designed to
evaluate the effects of ezetimibe added to atorvas-
tatin, compared with atorvastatin monotherapy, on
coronary plaque regression and a change in the lipid
proﬁle in patients with CAD.
METHODS
PRECISE–IVUS was a prospective, randomized, con-
trolled, assessor-blind, multicenter study to evaluate
the effect of ezetimibe added to atorvastatin on
coronary artery atheroma volume as measured byedical Sciences, Kumamoto University, Kumamoto,
mamoto, Japan; zDivision of Cardiology, Kumamoto
ine, Fukuoka Tokushukai Medical Center, Kasuga,
ta, Japan; {Division of Cardiology, Health Insurance
iseikai Kumamoto Hospital Cardiovascular Center,
atsudo, Japan; yyDivision of Coronary Artery Disease,
ya, Japan; zzDepartment of Community Medicine,
usa Medical Center, Amakusa, Japan; kkDivision of
, Miyazaki Prefectural Nobeoka Hospital, Nobeoka,
pital, Yatsushiro, Japan; ***Division of Cardiology,
, Yatsushiro, Japan; yyyDepartment of Cardiology,
pan; zzzDivision of Cardiology, Japanese Red Cross
amoto City Hospital, Kumamoto, Japan; and the
cular Center, Suita, Japan. This work was supported
rant-in-aid for Scientiﬁc Research C (26461075) from
Ogawa has received remuneration for lectures from
s received trust research/joint research funds from
AstraZeneca, Astellas, Bristol-Myers Squibb, Chugai,
noﬁ, Shionogi, and Takeda. Dr. Ishihara has received
ey have no relationships relevant to the contents of
ntin Fuster.
, accepted May 26, 2015.
J A C C V O L . 6 6 , N O . 5 , 2 0 1 5 Tsujita et al.
A U G U S T 4 , 2 0 1 5 : 4 9 5 – 5 0 7 Main Results of the PRECISE–IVUS Trial
497intravascular ultrasound (IVUS) in patients with CAD.
A detailed protocol of the PRECISE-IVUS trial was
described previously (7). The study complied with the
Declaration of the Helsinki with respect to investiga-
tion in humans, was approved by institutional review
committees, and conducted in accordance with the
guidelines of the ethics committee at participating
institutions. Written informed consent was obtained
from all patients.
Patients 30 to 85 years of age with CADwho satisﬁed
all criteria for inclusion were enrolled after having
undergone successful coronary angiography or
percutaneous coronary intervention (PCI) under IVUS
guidance to treat ACS or stable angina pectoris (SAP).
Participants were required to have an LDL-C level at
entry of >100 mg/dl. Eligible patients gave written
informed consent, and then were randomly assigned
in a 1:1 ratio to receive either atorvastatin (Lipitor,
Pﬁzer, New York, New York) alone (L group) orFIGURE 1 Flow Chart
24
LZ group (Atorvastatin + Ezetimibe)
Excluded from safety analysis: 1
Withdrew consent (1)
(n = 122) Assigned to receive
ACS: 63
SAP: 59
(n = 121) Safety analysis set
ACS: 62
SAP: 59
(n = 100) Full analysis set ACS: 51
SAP: 49
(n = 89) Per protocol set ACS: 47SAP: 42
IVUS not performed (15)
Final IVUS assessed before 9 months or
after 12 months from randomization (8)
Changed to another statin (1)
Quit taking study drugs (2)
IVUS not analyzable (6)
Did not complete endpoint assessment: 21
Protocol Violations: 11
246
Patients were randomized by treatment group and also followed by pres
alone group; LZ ¼ atorvastatin plus ezetimibe group; SAP ¼ stable angiatorvastatin plus ezetimibe (Zetia, Merck, Whitehouse
Station, New Jersey) 10mg/day (LZ group) using aweb-
based randomization software (Figure 1). Randomiza-
tion was stratiﬁed by: 1) sex; 2) age; 3) history of
hypertension; 4) history of diabetes; 5) history of
peripheral arterial disease; 6) serum LDL-C level; 7)
serum high-density lipoprotein cholesterol (HDL-C)
level; 8) serum triglyceride level; and 9) statin pre-
treatment before study enrollment. Atorvastatin was
increased by titration within the usual dose range with
a treatment goal of LDL-C <70 mg/dl on the basis of
published lipoprotein management guidelines (8).
Lipid proﬁles and other biomarker levels were
measured at baseline and follow-up at 9 to 12 months
(analyzed by SRL Co., Ltd., Tokyo, Japan) at partici-
pating institutions or general physician clinics that
conducted medical examinations and blood testing.
Participating clinicians were asked to continue
administration of the allocated drugs in accordance6 Patients enrolled
(n = 122) Safety analysis set ACS: 61SAP: 61
(n = 102) Full analysis set ACS: 49SAP: 53
(n = 89) Per protocol set ACS: 41SAP: 48
ACS: 63
SAP: 61(n = 124) Assigned to receive
L group (Atorvastatin alone)
 Patients randomized
Excluded from safety analysis: 2
Withdrew consent (2)
Final IVUS assessed before 9 months or
after 12 months from randomization (7)
Changed to another statin (3)
Quit taking study drugs (2)
Added ezetimibe (1)
Protocol Violations: 13
IVUS not performed (16)
IVUS not analyzable (4)
Did not complete endpoint assessment: 20
entation. ACS ¼ acute coronary syndrome(s); IVUS ¼ intravascular ultrasound; L ¼ atorvastatin
na pectoris.
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498with the previously described randomization and
titration protocol until the study’s end. Serial IVUS and
coronary angiography were performed at baseline and
again at 9- to 12-month follow-up at participating CV
centers. Safety was monitored throughout the study
and evaluated by periodic medical examination and
laboratory tests at 3, 6, and 9 to 12 months after
enrollment.
IVUS IMAGE ACQUISITION AND ANALYSIS. PRECISE-
IVUS used IVUS imaging to trace the lumen and vessel
border (external elastic membrane [EEM]) and to
evaluate coronary atheroma progression and/or
regression. Investigators were required to use the
same IVUS imaging system for both baseline and
follow-up IVUS image acquisition. The IVUS catheter
was advanced into a PCI or non-PCI vessel as far
distally possible to safely reach to obtain the longest
possible target segment for analysis, and it was then
withdrawn at a pull-back speed of 0.5 mm/s auto-
matically after intracoronary administration of nitro-
glycerin 0.1 to 0.2 mg. IVUS studies were archived
onto CD-ROMs or DVDs with study-speciﬁc identiﬁ-
cation numbers on an anonymous basis and sent to
an independent, treatment-allocation–blinded IVUS
core laboratory at the Department of Cardiovascular
Medicine, Graduate School of Medical Sciences,
Kumamoto University. The IVUS analysis was
performed by 2 independent experienced observers
(K.T. and K.S.) who were unaware of the treatment
allocation and temporal sequence of paired images
according to consensus standards (9). Baseline and
follow-up IVUS images were reviewed together on
a display, and target vessels and segments were
selected on the basis of the previously described
IVUS inclusion and/or exclusion criteria (7). Specif-
ically, the operator selected a target segment in both
the longest and least angulated segment that met the
inclusion criteria among the PCI or non-PCI vessels.
The target segment to be monitored was determined
in a non-PCI site (>5 mm proximal or distal to the PCI
site) with a reproducible ﬁduciary index, usually a
side branch, as the beginning and endpoint of the
segments to be analyzed. Patients who met pre-
speciﬁed requirements for IVUS image quality were
then eligible for the full analysis set. Coronary
atheroma parameters of the selected target segment
were assessed by volumetric analysis with the
echoPlaque3 system (INDEC Systems, Inc., Mountain
View, California). Intra- and interobserver re-
producibilities for measuring the primary efﬁcacy
endpoint by 2 independent IVUS analysts were
assessed in 50 randomly selected plaques. The cor-
relation coefﬁcient and mean difference  SD were
0.999 and 0.002  0.121% (of the absolute meanvalue; –1.379  2.473%, of the samples) for intra-
observer variability and 0.981 and 0.015  0.474% for
interobserver variability, with good agreement be-
tween analysts.
On the basis of expert consensus (9), the primary
efﬁcacy endpoint was the absolute change in percent
atheroma volume (PAV) of the coronary selected
target segment from baseline to follow-up. The PAV
was calculated as follows:
PAV ¼ S ðEEM CSAelumen CSAÞ
S EEM CSA
 100
where EEM CSA is the cross-sectional area of the EEM
border, and the lumen CSA is the cross-sectional area
of the lumen border. For PAV, the summation of the
EEM CSA minus the lumen CSA was performed ﬁrst.
This value was then divided by the summation of the
EEM CSA, which was ﬁnally multiplied by 100. The
absolute change in PAV was calculated as the PAV at
9- to 12-month follow-up minus the PAV at baseline.
The secondary efﬁcacy endpoint was percent change
in normalized total atheroma volume (TAV), which
was calculated as follows:
TAVnormalized ¼
S ðEEMCSAelumenCSAÞ
no:of analyzed frames per patients
mediannumber of analyzed
frames in the population
For TAV, the summation of the EEM CSA minus the
lumen CSA was performed ﬁrst. This value was
divided by the number of analyzed frames in the
pullback and then multiplied by the median number
of analyzed frames in the study population. The
average plaque area in the pullback was multiplied by
the median number of images analyzed in the entire
cohort to compensate for differences in segment
length between subjects.
BIOMARKER ASSESSMENT. The secondary endpoints
included absolute and percent changes in the lipid,
glycemic, and inﬂammatory proﬁle [total choles-
terol, LDL-C, triglyceride, HDL-C, HDL2-C, HDL3-C,
malondialdehyde-modiﬁed LDL-C, remnant-like li-
poprotein particle cholesterol, small-dense LDL-C,
free-fatty acid, apolipoprotein A-I, apolipoprotein B,
apolipoprotein C-II, apolipoprotein C-III, lipopro-
tein(a), fasting insulin level, glycosylated hemoglo-
bin, adiponectin, lathosterol, cholestanol, sitosterol,
campesterol, and high-sensitivity C-reactive protein]
during the study period.
STATISTICAL ANALYSIS. Statistical analysis was per-
formed using SPSS Statistics for Windows (version
22.0; IBM Corp., Armonk, New York). After the de-
scriptive statistics, continuous variables (mean  SD
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499and medians with interquartile ranges) between the
2 groups were compared using the unpaired Student t
test or the Mann-Whitney U test. Continuous vari-
ables between the baseline and follow-up were
compared by 1-sample Student t tests or the Wil-
coxon signed rank test according to their distri-
butions. Categorical variables (frequencies) were
compared using chi-square statistics or the Fisher
exact test. The relationships between the absolute
change in PAV and several factors, including follow-
up LDL-C level and the cholesterol absorption
marker, were evaluated with a simple regression
analysis. The full analysis dataset, in which the pa-
tients had measurable IVUS images both at baselineTABLE 1 Clinical Demographics Between Groups
Full Study Cohort
LZ Group
(n ¼ 100)
L Group
(n ¼ 102)
Age, yrs 66  10 67  10
Male 78 (78) 80 (78)
Weight, kg 67.1  13.2 65.7  10.8
Body mass index, kg/m2 24.8  3.4 24.9  3.1
Hypertension 75 (75) 67 (66)
Diabetes mellitus
Insulin 4 (4) 4 (4)
Noninsulin 25 (25) 27 (26)
HbA1c, % 5.4 (5.1–6.2) 5.5 (5.3–6.3)
Dyslipidemia 72 (72) 70 (69)
Current smoking 20 (20) 33 (32)
Presentation of ACS
STEMI
NSTEMI N/A N/A
Unstable angina
History of PCI 19 (19) 15 (15)
History of CABG 0 0
History of MI 15 (15) 13 (13)
History of stroke 10 (10)* 1 (1)
History of PAD 3 (3) 4 (4)
Previous statin use 46 (46) 49 (48)
Concomitant medication
Aspirin 100 (100) 102 (100)
Thienopyridines† 100 (100) 101 (99)
Cilostazol 1 (1) 0
Sarpogrelate hydrochloride 2 (2) 2 (2)
Warfarin 5 (5) 1 (1)
Nitrates 6 (6) 14 (14)
Beta-blockers 41 (41) 51 (50)
Calcium blockers 44 (44) 35 (34)
ACE inhibitors 25 (25) 28 (27)
ARBs 48 (48) 37 (36)
Stomach medicines 89 (89) 89 (87)
Hypoglycemic agents 25 (25) 25 (25)
Values are mean  SD, n (%), or median (interquartile range [IQR]). *The signiﬁcant be
ACE ¼ angiotensin-converting enzyme; ACS ¼ acute coronary syndrome(s); ARB ¼
glycosylated hemoglobin; L ¼ atorvastatin alone; LZ ¼ atorvastatin/ezetimibe; MI ¼ myo
peripheral artery disease; PCI ¼ percutaneous coronary intervention; SAP ¼ stable anginand at follow-up, was used for the primary analyses.
The per-protocol dataset analysis was also speciﬁed if
the enrolled patients completely met the inclusion
and exclusion criteria and were followed according
to protocol. If patients received the study drugs
at least once, they were included in the safety anal-
ysis. The number of adverse events was assessed
to determine safety proﬁles. A p value <0.05 was
considered signiﬁcant.
The PRECISE-IVUS trial aimed to evaluate whether
the effect of atorvastatin/ezetimibe on coronary
atheroma regression would not be inferior to that of
atorvastatin monotherapy. A detailed structure of
statistical analyses in the present study was describedACS Cohort SAP Cohort
LZ Group
(n ¼ 51)
L Group
(n ¼ 49)
LZ Group
(n ¼ 49)
L Group
(n ¼ 53)
64  11 65  10 67  8 68  10
41 (80) 41 (84) 37 (76) 39 (74)
68.3  13.6 67.0  12.1 65.8  12.8 64.6  9.5
24.9  3.5 24.8  3.0 24.6  3.3 25.1  3.2
38 (75) 28 (57) 37 (76) 39 (74)
1 (2) 2 (4) 3 (6) 2 (4)
11 (22) 11 (22) 14 (29) 16 (30)
5.3 (5.2–6.0) 5.6 (5.3–6.3) 5.6 (5.2–6.4) 5.5 (5.3–6.3)
33 (65) 37 (76) 39 (80) 33 (62)
13 (25) 22 (45) 7 (14) 11 (21)
26 (51) 25 (51)
5 (10) 7 (14) N/A N/A
20 (39) 17 (35)
3 (6) 5 (10) 16 (33) 10 (19)
0 0 0 0
4 (8) 4 (8) 11 (22) 9 (17)
4 (8) 1 (2) 6 (12)* 0
1 (2) 1 (2) 2 (4) 3 (6)
22 (43) 26 (53) 24 (49) 23 (43)
51 (100) 49 (100) 49 (100) 53 (100)
51 (100) 48 (98) 49 (100) 53 (100)
0 0 1 (2) 0
1 (2) 1 (2) 1 (2) 1 (2)
4 (8) 0 1 (2) 1 (2)
5 (10) 4 (8) 1 (2)† 10 (19)
29 (57) 29 (59) 12 (24) 22 (42)
21 (41) 11 (22) 23 (47) 24 (45)
17 (33) 19 (39) 8 (16) 9 (17)
23 (45) 13 (27) 25 (51) 24 (45)
49 (96) 45 (92) 40 (82) 44 (83)
9 (18) 11 (22) 16 (33) 14 (26)
tween-group difference with a p <0.05. †Clopidogrel, prasugrel, and ticlopidine.
angiotensin II receptor blocker; CABG ¼ coronary artery bypass grafting; HbA1c ¼
cardial infarction; NSTEMI ¼ non–ST-segment elevation myocardial infarction; PAD ¼
a pectoris; STEMI ¼ ST-segment elevation myocardial infarction.
TABLE 2 Baseline an
TC, mg/dl
HDL-C, mg/dl
LDL-C, mg/dl
Triglycerides, mg/dl
Lipoprotein (a), mg/dl
Apolipoprotein A-I, mg
Apolipoprotein B, mg/d
Free fatty acid, mEq/l
MDA-LDL, U/l
RLP-C, mg/dl
sdLDL-C, mg/dl
Insulin, mIU/ml
HbA1c, %
Total adiponectin, mg/m
HMW adiponectin, mg/m
Lathosterol, mg/ml
Campesterol, mg/ml
Sitosterol, mg/ml
Lathosterol, mg/100 m
Campesterol, mg/100 m
Sitosterol, mg/100 mg
Campesterol/lathostero
hs-CRP, mg/l
Values are mean  SD or m
HDL-C ¼ high–density lip
modiﬁed LDL; RLP-C ¼ rem
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500elsewhere (7). According to the pre-speciﬁed non-
inferiority margin and sample size calculation, in-
vestigators established a noninferiority margin of 3%,
and calculated that 100 subjects were needed in each
group, with an alpha level of 5% that gave power of
80%. A key secondary objective was to determine
whether the atorvastatin/ezetimibe combination was
superior to atorvastatin monotherapy with respect to
the nominal change in coronary PAV.
RESULTS
From June 21, 2010, through April 22, 2013, a total of
246 patients were enrolled at 17 CV centers in Japan
and randomly assigned to receive atorvastatin plus
ezetimibe 10 mg/day (n ¼ 122) or atorvastatin alone
(n ¼ 124) (Figure 1). After 9 to 12 months of treatment,
202 patients (82%) remained for follow-up and un-
derwent repeat IVUS imaging. Of these patients, 100
were in the LZ group and 102 in the L group. The LZ
group experienced a slightly longer follow-up period
(10.1  1.8 months vs. 9.7  1.7 months; p ¼ 0.10).
There were no signiﬁcant differences in demo-
graphic characteristics or baseline medication used Follow-Up Laboratory Data
Baseline Follow-
LZ Group
(n ¼ 100)
L Group
(n ¼ 102)
LZ Group
(n ¼ 100)
177.3  32.4 172.7  32.6 129.4  22.0
41.1  9.5 40.0  10.3 45.6  11.9
109.8  25.4 108.3  26.3 63.2  16.3
114 (81 to 158) 116 (92 to 159) 92 (76 to 120)
21.5 (12.5 to 37.5) 18.0 (10.0 to 30.5) 17.0 (8.0 to 36.0)
/dl 112.8  20.2 112.6  21.6 128.1  25.0
l 96.9  20.6 94.0  19.2 62.5  13.0
402 (281 to 574) 431 (278 to 610) 384 (218 to 541)
122.9  39.9 121.8  40.5 81.8  24.1
3.8 (2.7 to 4.8) 3.5 (2.7 to 5.1) 2.6 (2.1 to 3.5)
32.7  15.6 30.5  11.8 20.6  8.6
6.8 (4.3 to 10.1) 7.3 (4.9 to 9.6) 7.9 (4.9 to 12.6)
5.4 (5.1 to 6.3) 5.5 (5.3 to 6.3) 5.6 (5.2 to 6.0)
l 4.7 (3.4 to 7.0) 4.1 (2.7 to 5.7) 6.2 (3.9 to 8.3)
l 1.9 (1.0 to 3.1) 1.4 (0.8 to 2.6) 2.3 (1.2 to 4.3)
1.1 (0.7 to 2.3) 1.3 (0.7 to 2.1) 1.0 (0.8 to 1.4)
4.4 (3.3 to 5.7) 3.7 (2.8 to 5.0) 2.3 (1.8 to 2.9)
2.2 (1.7 to 3.0) 2.0 (1.5 to 2.7) 1.3 (1.0 to 1.9)
g TC 68 (43 to 109) 73 (44 to 116) 81 (59 to 108)
g TC 252 (199 to 321) 215 (165 to 281) 183 (143 to 228)
TC 129 (98 to 174) 113 (91 to 152) 101 (78 to 145)
l 3.7 (2.2 to 6.5) 2.8 (2.0 to 5.0) 2.2 (1.5 to 3.6)
3.0 (1.0 to 14.9) 3.7 (1.2 to 8.1) 0.4 (0.2 to 1.3)
edian (IQR).
oprotein cholesterol; HMW ¼ high molecular weight; hs-CRP ¼ high-sensitivity C-reactive
nant like particles cholesterol; sdLDL-C ¼ small-dense LDL-C; TC ¼ total cholesterol; othebetween the 2 treatment groups, except for history
of stroke and frequency of nitrate use (Table 1).
PRECISE-IVUS investigators enrolled patients with
both ACS and SAP; eventually, one-half of the study
patients were assigned to the ACS cohort; the others
to the SAP cohort. The majority of patients (78%) were
men, and 30% of the total study patients had dia-
betes. Among those with ACS, the clinical presenta-
tion was ST-segment elevation myocardial infarction
in 51%. In terms of concomitant medication, the ma-
jority of patients were treated with optimal medical
therapy in addition to lipid-lowering study drugs.
Baseline and follow-up laboratory data are shown in
Table 2. Although LDL-C levels were similar between
the 2 groups at baseline, LDL-C level was signiﬁcantly
lower at 9 to 12 months in the LZ group than in the L
group (p < 0.001), and the dual lipid-lowering strategy
showed more remarkable reduction of LDL-C level
than atorvastatin monotherapy during the study
(p<0.001). These values resulted in the LZ group expe-
riencing a lower ratio of LDL-C to HDL-C during treat-
ment (1.45  0.45 vs. 1.77  0.55; p < 0.001) and having
a greater proportion of patients who achieved LDL-C
levels <70 mg/dl (72% vs. 47%; p ¼ 0.001) comparedUp Percent Change (%)
L Group
(n ¼ 102)
LZ Group
(n ¼ 100)
L Group
(n ¼ 102) p Value
138.7  26.2 –25  17 –18  18 0.006
43.3  11.5 14  26 11  25 0.5
73.3  20.3 –40  18 –29  24 <0.001
111 (87 to 139) –14 (–33 to 18) –9 (–33 to 25) 0.3
14.0 (7.0 to 30.5) –12 (–42 to 17) –20 (–50 to 7) 0.1
123.7  24.5 15  21 11  17 0.2
69.0  16.1 –34  16 –26  20 0.001
376 (223 to 627) –7 (–50 to 59) –11 (–56 to 68) 0.8
95.1  30.8 –27.7  27.0 –15.3  38.5 0.1
3.1 (2.4 to 4.5) –28 (–48 to 3) –17 (–37 to 17) 0.02
22.5  10.1 –28.5  33.5 –21.4  35.0 0.2
8.4 (5.4 to 12.5) 15 (–33 to 73) 22 (–18 to 51) 0.99
5.7 (5.4 to 6.1) 3 (–2 to 5) 2 (–4 to 4) 0.2
5.0 (3.3 to 7.2) 28 (–4 to 64) 19 (–5 to 63) 0.4
1.6 (0.9 to 2.9) 24 (–25 to 74) 19 (–25 to 86) 0.9
0.6 (0.4 to 0.9) –15 (–53 to 45) –53 (–71 to –22) <0.001
4.9 (3.5 to 6.4) –46 (–61 to –30) 22 (–5 to 61) <0.001
2.4 (1.8 to 3.4) –39 (–53 to –20) 31 (–6 to 67) <0.001
49 (33 to 66) 14 (–28 to 68) –36 (–57 to 2) <0.001
362 (258 to 451) –30 (–43 to –10) 53 (24 to 82) <0.001
178 (131 to 264) –15 (–34 to 9) 60 (27 to 106) <0.001
7.5 (4.3 to 12.5) –40 (–66 to 10) 167 (48 to 267) <0.001
0.3 (0.2 to 0.8) –89 (–97 to –59) –86 (–95 to –70) 0.9
protein; LDL-C ¼ low-density lipoprotein cholesterol; MDA-LDL ¼ malondialdehyde–
r abbreviations as in Table 1.
TABLE 3 Demonstration of Coronary Plaque Progression/Regression
Baseline 9–12 Months Follow-Up
LZ Group
(n ¼ 100)
L Group
(n ¼ 102) p Value
LZ Group
(n ¼ 100)
L Group
(n ¼ 102) p Value
Plaque volume, mm3 72.6 (37.6 to 117.4) 76.3 (45.5 to 128.4) 0.5 69.6 (35.0 to 107.2) 77.3 (45.4 to 126.2) 0.2
Percent atheroma volume, % 51.3  10.8 50.9  11.4 0.8 49.3  10.3 50.4  11.6 0.5
TAV norm, mm
3 89.6 (65.8 to 118.8) 84.8 (61.5 to 112.7) 0.7 85.4 (65.5 to 110.0) 87.2 (60.1 to 111.8) 0.6
Vessel volume, mm3 144.4 (78.5 to 218.6) 159.8 (97.7 to 244.4) 0.3 141.8 (70.0 to 222.3) 155.7 (101.4 to 241.6) 0.2
Lumen volume, mm3 70.4 (34.5 to 117.1) 79.4 (47.5 to 116.6) 0.3 65.8 (36.5 to 113.8) 79.1 (47.7 to 115.3) 0.2
Lesion length, mm 10.1 (5.6 to 14.6) 12.4 (7.5 to 16.0) 0.11 9.7 (5.8 to 14.5) 11.9 (7.2 to 15.9) 0.10
Absolute Change
LZ Group
(n ¼ 100)
p Value Compared
With Baseline
L Group
(n ¼ 102)
p Value Compared
With Baseline p Value Between Groups
Plaque volume, mm3 -3.9 (-10.6 to 0.0) <0.001 -1.0 (-6.8 to 5.7) 0.4 0.001
Percent atheroma volume, % -1.4 (-3.4 to -0.1) <0.001 -0.3 (-1.9 to 0.9) 0.03 0.001
ACS cohort -2.3 (-3.7 to -0.5) <0.001 -0.2 (-1.3 to 0.5) 0.2 <0.001
SAP cohort -1.2 (-2.2 to -0.1) 0.001 -0.7 (-2.3 to 1.1) 0.08 0.2
TAV norm, mm
3 -5.3 (-12.4 to 0.1) <0.001 -1.2 (-5.7 to 3.3) 0.1 <0.001
Vessel volume, mm3 -4.1 (-12.6 to 3.1) 0.001 -0.6 (-11.8 to 10.6) 0.9 0.04
Lumen volume, mm3 -0.3 (-4.9 to 4.0) 0.4 0.8 (-5.6 to 6.9) 0.5 0.4
Percent Change (%)
LZ Group
(n ¼ 100)
p Value Compared
With Baseline
L Group
(n ¼ 102)
p Value Compared
With Baseline p Value Between Groups
Plaque volume, mm3 -5.2 (-15.1 to 0.0) N/A -1.3 (-8.6 to 6.5) N/A <0.001
TAV norm, mm
3 -6.6 (-12.6 to 0.2) N/A -1.4 (-6.7 to 4.4) N/A <0.001
ACS cohort -10.2 (-13.6 to -3.8) N/A -1.3 (-6.7 to 4.4) N/A <0.001
SAP cohort -5.0 (-10.3 to 1.2) N/A -1.5 (-6.3 to 4.0) N/A 0.08
Vessel volume, mm3 -2.5 (-9.0 to 2.5) N/A -0.3 (-6.5 to 7.9) N/A 0.04
Lumen volume, mm3 -0.6 (-7.2 to 7.4) N/A 0.9 (-7.2 to 11.6) N/A 0.4
Values are median (IQR) or mean  SD.
TAV ¼ total atheroma volume; other abbreviations as in Table 1.
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501with the L group. Although there was no difference
between the 2 groups in percent change of high-
sensitivity C-reactive protein, cholesterol absorption
markers—campesterol, sitosterol, campesterol-to-
cholesterol ratio, sitosterol-to-cholesterol ratio, and
campesterol-to-lathosterol ratio—were all signiﬁ-
cantly decreased in the LZ group frombaseline to 9 to 12
months of follow-up. Those levels were signiﬁcantly
increased in the L group.
IVUS ANALYSIS RESULTS. Table 3 shows the IVUS
efﬁcacy endpoints at each time point and the serial
changes (Central Illustration). Analyses were per-
formed on data from the full analysis set population
(Figure 1); comparison of the primary endpoint was
analyzed as part of hierarchical sequence testing
(starting with testing of the primary endpoint for
noninferiority, and then testing superiority) to con-
trol for the type I error. The primary endpoint (non-
inferiority of the LZ to the L group in absolute change
in PAV) was proved (Figure 2), with a mean difference
of drug effects on absolute change in PAV of –1.538%
(95% conﬁdence interval [CI]: –3.079% to 0.003%).The upper limit of the 95% CI did not exceed the pre-
deﬁned noninferiority margin of 3% (7). For superi-
ority, the absolute change in PAV decreased by –1.4%
(–3.4% to –0.1%) in the LZ group and by –0.3% (–1.9%
to 0.9%) in the L group (p < 0.001 for the change from
baseline in the LZ group and p ¼ 0.03 in the L group;
p ¼ 0.001 for the between-group comparison). For
PAV, a signiﬁcantly greater percentage of patients of
the LZ group showed coronary plaque regression
(78% vs. 58%; p ¼ 0.004).
For percent change in TAVnormalized, a secondary
IVUS endpoint, the effect was more favorable in the
LZ group than in the L group (–6.6%; 95% CI: –12.6%
to 0.2% vs. –1.4%; 95% CI: –6.7% to 4.4%; p < 0.001).
For TAVnormalized, a signiﬁcantly greater proportion of
the LZ group patients had disease regression (75% vs.
58%; p ¼ 0.02).
With regard to vessel remodeling during follow-up,
the vessel volume of the target segment analyzed was
negatively remodeled in the LZ group versus the L
group, although the lumen volume serial change was
comparable between the groups.
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502Similar results were conﬁrmed even in the “per
protocol set” cohort (Online Table 1).
After classifying the entire study cohort into either
an ACS or SAP cohort, the between-group difference of
the plaque regression effect (the more prominent pla-
que regression effect in the LZ group compared with
the L group) was greater in the ACS cohort, in terms of
both the absolute change in PAV and the percent
change in TAVnormalized. This suggested that aggres-
sive dual lipid-lowering with atorvastatin/ezetimibe
might reverse the coronary plaque developmentTRATION Relationship Between Achieved Low-Density Lipop
a Volume for Previous Intravascular Ultrasound Trials and t
Coll Cardiol. 2015; 66(5):495–507.
se correlation between achieved low-density lipoprotein cholesterol (LDL-C
ultrasound trials (r2 ¼ 0.926). Even in the stable angina pectoris cohort of
s Inhibitor Evaluated by Intravascular Ultrasound) trial, these plots are located
e line in the atorvastatin/ezetimibe combination arm of the acute coronary syn
n the atorvastatin monotherapy arm. ACS ¼ acute coronary syndrome(s); AS
Derived Coronary Atheroma Burden; Atorva ¼ atorvastatin; DPAV ¼ absolut
al of Atherosclerosis With Aggressive Lipid-Lowering; SAP ¼ stable angina p
f Rosuvastatin versus Atorvastatin.process in patients with ACS rather than with SAP
(Central Illustration). Representative serial changes of
the plaque progression and/or regression visualized by
IVUS in both groups are shown in Figure 3.
Table 4 compares laboratory data between the pa-
tient groupswith plaque regression versus progression
in PAV. Compared with patients with plaque pro-
gression (any positive change in PAV), the achieved
LDL-C level was signiﬁcantly suppressed in patients
with plaque regression (any negative change in
PAV), as well as apolipoprotein B and small-denserotein Cholesterol Levels and the Median Change in
he PRECISE–IVUS Trial
) levels and the median change in percent atheroma volume in
the PRECISE-IVUS (Plaque Regression With Cholesterol Absorption
in range with the pre-existing regression line. In contrast, the plot is
drome cohort of the PRECISE-IVUS trial, whereas the plot was still in
TEROID ¼ A Study to Evaluate the Effect of Rosuvastatin on Intra-
e change in percent atheroma volume; Prava ¼ pravastatin;
ectoris; SATURN ¼ Study of Coronary Atheroma by Intravascular
FIGURE 2 Primary Endpoint: Absolute Change in PAV
Mean (95% Confidence Interval)
-1.538 (-3.079 – 0.003)
-3% 0%
prespecified
noninferiority
margin
noninferior
LZ Group Better L Group Better
“not” noninferior
3%
μLZ - μL (%) 
The atorvastatin/ezetimibe (LZ) group was noninferior to the atorvastatin-alone (L) group in terms of the primary endpoint, which was
the absolute change in percent atheroma volume (PAV). mLZ – mL indicates the difference of drug effects on absolute change in PAV, where
mLZ represents the absolute change in PAV in the LZ group and mL represents that of the L group.
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503LDL-C. Among cholesterol absorption markers, the
campesterol-to-cholesterol ratio tended to be lower in
the regression group versus the progression group. As
shown in Figure 4, relationships between theseFIGURE 3 Plaque Progression/Regression
Baseline
PB: 50.2%
LZ Group (ACS)
*
* *
*
LZ Group (SAP)
Follow-Up
PB: 44.0%
Baseline
PB: 49.8%
Follow-Up
PB: 48.8%
IVUS images of the same cross sections at baseline and follow-up show
membrane (red line). Note the substantial reduction in plaque area obse
the L group.*Side branches show same position and shape. PB ¼ plaquebiomarkers and the absolute change in PAV were
evaluated using linear regression analysis in the full
study, ACS, and SAP cohorts. Similar to a recent IVUS
study (10), there were no strong correlations between* *
* *
L Group (ACS)
L Group (SAP)
Baseline
PB: 53.6%
Follow-Up
PB: 50.7%
Baseline
PB: 50.9%
Follow-Up
PB: 51.1%
outlined leading edges of lumen (yellow line) and external elastic
rved for the cross-sectional images, especially in the LZ group versus
burden; other abbreviations as in Figures 1 and 2.
TABLE 4 Comparison Between PAV Regression and Progression
Regression in PAV
(n ¼ 135)
Progression in PAV
(n ¼ 67) p Value
TC, mg/dl 130.6  24.0 141.5  24.3 0.006
HDL-C, mg/dl 44.0  12.2 45.3  10.7 0.2
LDL-C, mg/dl 65.5  17.8 74.3  20.3 0.003
Ratio of LDL-C/HDL-C 1.57  0.51 1.71  0.54 0.08
Triglycerides, mg/dl 95.0 (76.0–126.5) 102.0 (85.0–142.0) 0.2
Lipoprotein(a), mg/dl 15.0 (8.0–32.0) 16.0 (8.0–32.5) 0.8
Apolipoprotein A–I, mg/dl 124.0  25.6 130.0  22.6 0.04
Apolipoprotein B, mg/dl 64.1  14.6 69.3  15.2 0.02
Free fatty acid, mEq/l 393.0 (232.0–546.5) 329.0 (195.0–635.5) 0.2
MDA-LDL, U/l 86.9  26.3 92.0  32.4 0.4
RLP cholesterol, mg/dl 2.8 (2.2–3.7) 3.1 (2.4–4.7) 0.4
sdlDL cholesterol, mg/dl 20.4  8.6 24.1  10.6 0.02
Lathosterol, mg/100 mg TC 63.5 (43.5–91.2) 57.7 (44.3–85.3) 0.8
Campesterol, mg/100 mg TC 225.0 (174.4–356.9) 261.9 (207.1–395.8) 0.1
Sitosterol, mg/100 mg TC 136.9 (93.2–189.8) 156.5 (104.3–206.2) 0.2
Campesterol/lathosterol 3.8 (2.0–7.6) 4.2 (2.8–8.0) 0.8
Values are mean  SD or median (IQR).
PAV ¼ percent atheroma volume; other abbreviations as in Tables 1 and 2.
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504these biomarkers and absolute change in PAV. In the
achieved LDL-C level at follow-up (Figures 4A to 4C)
and the percent change in the campesterol-to-
cholesterol ratio during follow-up (Figures 4D to 4F),
despite theweak correlation, the steeper positive slope
of the regression line was notedmore in the ACS cohort
than the SAP cohort, which suggested plaque devel-
opment reversibility in patients with ACS.
Online Table 2 shows the clinical events,
laboratory abnormalities, and reasons for study drug
discontinuation. Both strategies were well tolerated
throughout the study. For both groups, the frequency
of CV events was similar, the rate of abnormal labo-
ratory values was low, and the rate of target lesion/
vessel revascularization was similar.
DISCUSSION
The major ﬁndings of PRECISE-IVUS include: 1)
the dual lipid-lowering strategy that combined ator-
vastatin and ezetimibe resulted in a more remarkable
reduction of LDL-C than atorvastatin monotherapy,
with suppression of the compensatory enhancement
of cholesterol absorption during 9 to 12 months of
follow-up; 2) volumetric IVUS analysis demonstrated
not only the noninferiority of the combination ther-
apy in terms of absolute change in PAV, but also the
superiority with regard to coronary plaque regression
with negative vascular remodeling in the analyzed
target segment; and 3) the signiﬁcant favorable
effect of the dual lipid-lowering strategy on the cor-
onary atherosclerotic development was pronounced,especially in the ACS cohort, along with a reduction of
cholesterol absorption markers and lower LDL-C
levels.
The large-scale clinical trials that evaluated com-
bined statin/ezetimibe therapy did not necessarily
generate positive results. In the ENHANCE (Ezetimibe
and Simvastatin in Hypercholesterolemia Enhances
Atherosclerosis Regression) trial (11), the simvastatin/
ezetimibe combination failed to show a signiﬁcant
difference in intima-media thickness versus simva-
statin alone. In addition, there were no differences in
the preventive effect on major CV events in the SEAS
(Simvastatin and Ezetimibe in Aortic Stenosis) trial,
which was conducted in patients with aortic stenosis
(12), whereas the SHARP (Study of Heart and Renal
Protection) trial provided evidence for safe and
effective lowering of LDL-C with a combination of
simvastatin/ezetimibe in a wide range of patients
with chronic kidney disease (13). However, when the
“coronary ischemic events” speciﬁcally mentioned in
the SEAS trial were examined, the combination of
simvastatin/ezetimibe was signiﬁcantly superior to
placebo in terms of the preventive effect on ischemic
heart disease (12). The IMPROVE-IT trial (6) was the
ﬁrst to demonstrate an incremental clinical beneﬁt by
adding a nonstatin agent to standard statin therapy,
and proposed that the dual lipid-lowering strategy
with statin/ezetimibe was a promising novel anti-
atherosclerotic strategy in patients with residual risk.
Compared with simvastatin plus placebo, simva-
statin/ezetimibe reduced atherosclerotic CV events,
namely, ischemic stroke by 21% and myocardial
infarction by 13%, which led to a signiﬁcantly lower
incidence of the primary combined CV endpoint.
In terms of the lipid proﬁle in IMPROVE-IT trial
participants, mean LDL-C was signiﬁcantly lower
in patients treated with simvastatin and ezetimibe
relative to those treated with simvastatin mono-
therapy (53 mg/dl vs. 70 mg/dl at 1 year), and the
trial reafﬁrmed the LDL-C hypothesis that reducing
LDL-C prevents CV events.
A large meta-analysis using IVUS plaque progres-
sion and/or regression studies demonstrated a direct
relationship between the burden of coronary athero-
sclerosis, its progression, and adverse CV events (14).
Our PRECISE-IVUS trial conﬁrmed noninferiority and
superiority of coronary plaque regression using the
combination of atorvastatin/ezetimibe over atorva-
statin alone. Therefore, the clinical event risk reduc-
tion in the IMPROVE-IT trial might be derived from
the suppression effect of coronary atherosclerotic
development by dual lipid lowering. In addition,
mean LDL-C levels were closely correlated with me-
dian change in PAV in several IVUS trials (15–18). With
FIGURE 4 Correlation Between Absolute Change in PAV and Biomarkers
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The relationship between the absolute change in PAV and biomarkers at 9 to 12 months of follow-up is demonstrated with the low-density lipoprotein cholesterol
(LDL-C) level in the (A) full study, (B) ACS, and (C) SAP cohorts, as well as with the percent change in the campesterol-to-cholesterol ratio in the (D) full study, (E) ACS,
and (F) SAP cohorts. Abbreviations as in Figure 1.
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505regard to the lipid-lowering effects of a statin/ezeti-
mibe combination, even in the present PRECISE–IVUS
trial, the dual lipid-lowering strategy was associated
with lower LDL-C levels at follow-up and greater
reduction in LDL-C during the study compared with
statin monotherapy, which is similar to previous
studies (6,19). Our results reafﬁrmed the relationship
between the achieved lower LDL-C level and coronary
plaque regression. Conversely, because the study
protocol demanded that participating physicians
target LDL-C to <70 mg/dl, the higher achieved
LDL-C levels in patients treated with atorvastatin
alone demonstrated clinical limitations of statin
monotherapy in lipid-lowering and antiathero-
sclerotic effects against coronary plaque.
Another possible mechanism underlying the clin-
ical beneﬁt obtained by dual lipid lowering was the
suppression of the compensatory enhancement of
cholesterol absorption. The DEBATE (Drugs and
Evidence-Based Medicine in the Elderly) study
showed that mortality increased with increasinglevels of the cholesterol absorption marker, the
cholestanol-to-cholesterol ratio (20). The present
study found a positive correlation between the sup-
pression of cholesterol absorption markers and coro-
nary plaque regression, which reconﬁrmed the
inhibitory effect of ezetimibe added to statin-induced
accelerated cholesterol absorption markers. Further-
more, a previous optical coherence tomography study
suggested plaque stabilization using a ﬂuvastatin/
ezetimibe combination, which showed a thickened
ﬁbrous cap that protected lipid-rich plaque in pa-
tients treated by dual lipid lowering compared with
ﬂuvastatin monotherapy (19).
As described previously, a close relationship exists
between the achieved LDL-C level and coronary
plaque regression, and the cutoff point when coronary
atherosclerotic development turned from plaque
progression to regression was an achieved LDL-C level
at approximately 75 mg/dl (15). The achieved LDL-C
level was signiﬁcantly suppressed in patients with
plaque regression compared with patients with plaque
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Combination therapy with atorvastatin plus ezetimibe
was associated with greater coronary plaque regres-
sion than atorvastatin alone in patients who under-
went PCI.
TRANSLATIONAL OUTLOOK: Additional studies
are needed to ascertain the mechanism by which
ezetimibe accelerates plaque regression in this situa-
tion compared with statin monotherapy.
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506progression (Table 4). A systematic review demon-
strated that statin/ezetimibe combination therapy
(especially with strong statins) could help attain the
previously recommended strict LDL-C goals of <70
mg/dl (21). Although the new cholesterol treatment
guidelines released by the ACC/AHA emphasizes
matching the intensity of statin treatment to the level
of atherosclerotic CV disease risk (“ﬁre and forget”
concept), which replaces the old paradigm of pursuing
LDL-C goals (“treat to target” concept) (4), our positive
results from the PRECISE-IVUS trial could lead to an
early re-evaluation of the new ACC/AHA lipid man-
agement guidelines that endorses statins as the only
recommended drugs for treating cholesterol-related
CV risk. Also, our results provide evidence that sup-
ports the concept that ezetimibe added to standard
statin therapy can be effective in patients who are
unable to tolerate high-dose statins, those who may
better tolerate a combination of low-dose statin plus
ezetimibe, and those who cannot achieve adequate
LDL-C lowering despite high-dose statin use.
Finally, previous studies showed that statin-
induced coronary plaque regression appeared to be
more prominent in patients with ACS (–13.1% to –18.1%
in a median percentage of change in TAV) (10,22) than
in patients with SAP (–0.4% to –6.8% in a median per-
centage of change in TAV) (15,17). Although the asso-
ciation between coronary plaque regression induced
by statin therapy and patients’ clinical presentation
(stable or unstable status) has been speculated, this
association has not been validated by a study with a
prospective randomized design. Our ﬁndings from
PRECISE-IVUS conﬁrm that the correlated plaque
regression with lower achieved LDL-C level was espe-
cially evident in the ACS cohort, which suggests the
potential correlation between stronger plaque regres-
sion and the acute unstable presentation of vulnerable
patients. Therefore, the combination of statin/ezeti-
mibemight be a particularly effective treatment option
for vulnerable patients with a high risk of CAD
(e.g., such as individuals with high baseline LDL-C
values, diabetes, established CV disease, or familial
hypercholesterolemia).
STUDY LIMITATIONS. First, the present analysis
compared coronary plaque in patients treated with
standard statin monotherapy as a control cohort,
because it was not ethically acceptable to measure
disease progression and/or regression in placebo-
treated patients. Second, because the trial involved
patients who underwent PCI, it remains unknown
whether our ﬁndings could be applied to primary pre-
vention in patients without documented CAD. Third,
this study used IVUS imaging to examine diseaseprogression and/or regression, but newer analytical
methods might permit better characterization of coro-
nary plaque components. However, case samples that
could be evaluated by IVUS-derived tissue character-
ization software were limited. Fourth, it was reported
that thrombus,which is frequently seen in culprit lesions
of ACS, could not be detected by a traditional IVUS sys-
tem with high sensitivity and speciﬁcity. Therefore,
strict attention was paid to exclude thrombus in this
study. Fifth, although expert consensus recommends
that investigators acquire a segment that is as long as
possible because of the increase in variability when short
segments are analyzed, the analyzed segment length
was relatively short in our study because IVUS exami-
nation of non-PCI vessels tended to be avoided for
ethical and safety reasons, and the target segment to be
monitored was determined in a non-PCI site (>5 mm
proximal or distal to the PCI site) with reproducible ﬁ-
duciary indexes.
CONCLUSIONS
Among Japanese patients who underwent PCI,
aggressive lipid-lowering with dual inhibition of cho-
lesterol synthesis and absorption produced stronger
coronary plaque regression compared with sole inhi-
bition of the cholesterol biosynthetic pathway. Com-
bination therapy with statin plus ezetimibe might thus
be a promising lipid-lowering option for high-risk
patients.
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